Sfoglia per Autore
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
2012 Ludovini, V; Bianconi, Fortunato; Pistola, L; Minotti, V; Chiari, Rita; Colella, Renato; Bellezza, Guido; Tofanetti, Fr; Siggillino, A; Baldelli, E; Flacco, A; Giuffrida, D; Sidoni, Angelo; Crino', Lucio
Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY
2012 Faggiano, A; Ferolla, Piero; Grimaldi, F; Campana, D; Manzoni, M; Davi, Mv; Bianchi, A; Valcavi, R; Papini, E; Giuffrida, D; Ferone, D; Fanciulli, G; Arnaldi, G; Franchi, Gm; Francia, G; Fasola, G; Crino', Lucio; Pontecorvi, L; Tomassetti, P; Colao, A.
Impact of Crizotinib Treatment On Patient-reported Symptoms and Quality of Life (qol) In Advanced Alk-positive Non-small Cell Lung Cancer (nsclc)
2012 Blackhall, Fh; Evans, Tl; Han, J; Salgia, R; Moro Sibilot, D; Gettinger, S; Crino', Lucio; Wilner, K; Reisman, A; Iyer, S.
Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer
2012 Ludovini, V; Bellezza, Guido; Bianconi, Fortunato; Chiari, R; Bennati, C; Tofanetti, Fr; Vannucci, Jacopo; Puma, Francesco; Sidoni, Angelo; Crino', Lucio
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
2012 Reck, M; Barlesi, F; Crino', Lucio; Henschke, Ci; Isla, D; Stiebeler, S; Spigel, Dr
Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer
2012 Bianconi, Fortunato; K., Perruccio; V., Ludovini; E., Baldelli; Bellezza, Guido; A., Flacco; Ragusa, Mark; Valigi, Paolo; Crino', Lucio
Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc)
2012 Cappuzzo, F; Sacconi, A; Landi, L; Biagioni, F; Ludovini, V; Sensi, E; Salvini, J; Fontanini, G; Blandino, G; Crino', Lucio
Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial
2012 Ardizzoni, A; Tiseo, M; Boni, L; Vincent, Ad; Passalacqua, R; Buti, S; Amoroso, D; Camerini, A; Labianca, R; Genestreti, G; Boni, C; Ciuffreda, L; Costanzo, Fd; De Marinis, F; Crino', Lucio; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Mattioli, R; Cafferata, Ma; Camisa, R; Smit, Ef
Updated Results of A Global Phase II Study With Crizotinib In Advanced Alk-positive Non-small Cell Lung Cancer (NSCLC)
2012 Kim, D; Ahn, M; Yan, g P; Li, u X; Pas, Td; Crino', Lucio; Lanzalone, S; Polli, A; Shaw, A.
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.
2012 Riely, Gj; Brahmer, Jr; Planchard, D; Crino', Lucio; Doebele, Rc; Lopez, Lam; Gettinger, Sn; Schumann, C; Li, Xy; Atkins, Bm; Ebbinghaus, S; Rosell, R.
First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer
2012 Bearz, A; Passalacqua, R; Alabiso, O; Cinieri, S; Gridelli, C; Cravesana, C; Crino', Lucio
Emerging drugs for small cell lung cancer - an update
2012 Metro, G; Duranti, S; Fischer, Mj; Cappuzzo, F; Crino', Lucio
Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program.
2012 Normanno, N; Pinto, C; Taddei, Gl; Troncone, G; Graziano, P; Maglio, Gd; Mottolese, M; Ludovini, V; Zupo, S; Larocca, Lm; Roz, E; Russo, A; Palmieri, G; Perrone, G; Maio, Md; Ardizzoni, A; Crino', Lucio; Perrone, G; Clemente, C; Marchetti, A.
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer A Phase-II Study
2012 Scagliotti, Gv; Ilaria, R; Novello, S; Von Pawel, J; Fischer, Jr; Ermisch, S; De Alwis, Dp; Andrews, J; Reck, M; Crino', Lucio; Eschbach, C; Manegold, C.
Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).
2012 Janne, Pa; Shaw, At; Pereira, Jr; Jeannin, G; Vansteenkiste, J; Barrios, Ch; Franke, Fa; Grinsted, L; Smith, Pd; Zazulina, V; Smith, Ic; Crino', Lucio
Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study
2012 Faggiano, A; Grimaldi, F; Manzoni, M; Davi, Mv; Ferone, D; Giuffrida, D; Roiter, I; Fanciulli, G; Papini, E; Martini, C; Franchi, Gm; Fasola, G; Albertelli, M; Crino', Lucio; Colao, A; Ferolla, Piero
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
2012 Metro, G; Chiari, R; Duranti, S; Siggillino, Annamaria; Fischer, Mj; Giannarelli, D; Ludovini, V; Bennati, C; Marcomigni, L; Baldi, A; Giansanti, M; Minotti, V; Crino', Lucio
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
2012 Grunwald, V; Karakiewicz, Pi; Bavbek, Se; Miller, K; Machiels, Jp; Lee, Sh; Larkin, J; Bono, P; Rha, Sy; Castellano, D; Blank, Cu; Knox, Jj; Hawkins, R; Anak, O; Rosamilia, M; Booth, J; Pirotta, N; Bodrogi, I; Crino', Lucio; REACT Study, Group
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?
2012 Metro, G; Minotti, V; Crino', Lucio
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
2012 Miller, Va; Hirsh, V; Cadranel, J; Chen, Ym; Park, K; Kim, Sw; Zhou, Cc; Su, Wc; Wang, Mz; Sun, Y; Heo, Ds; Crino', Lucio; Tan, Eh; Chao, Ty; Shahidi, M; Cong, Xj; Lorence, Rm; Yang, Hjc
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. | 2012 | Ludovini, V; Bianconi, Fortunato; Pistola, L; Minotti, V; Chiari, Rita; Colella, Renato; Bellezza, Guido; Tofanetti, Fr; Siggillino, A; Baldelli, E; Flacco, A; Giuffrida, D; Sidoni, Angelo; Crino', Lucio | |
| Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY | 2012 | Faggiano, A; Ferolla, Piero; Grimaldi, F; Campana, D; Manzoni, M; Davi, Mv; Bianchi, A; Valcavi, R; Papini, E; Giuffrida, D; Ferone, D; Fanciulli, G; Arnaldi, G; Franchi, Gm; Francia, G; Fasola, G; Crino', Lucio; Pontecorvi, L; Tomassetti, P; Colao, A. | |
| Impact of Crizotinib Treatment On Patient-reported Symptoms and Quality of Life (qol) In Advanced Alk-positive Non-small Cell Lung Cancer (nsclc) | 2012 | Blackhall, Fh; Evans, Tl; Han, J; Salgia, R; Moro Sibilot, D; Gettinger, S; Crino', Lucio; Wilner, K; Reisman, A; Iyer, S. | |
| Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer | 2012 | Ludovini, V; Bellezza, Guido; Bianconi, Fortunato; Chiari, R; Bennati, C; Tofanetti, Fr; Vannucci, Jacopo; Puma, Francesco; Sidoni, Angelo; Crino', Lucio | |
| Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts | 2012 | Reck, M; Barlesi, F; Crino', Lucio; Henschke, Ci; Isla, D; Stiebeler, S; Spigel, Dr | |
| Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer | 2012 | Bianconi, Fortunato; K., Perruccio; V., Ludovini; E., Baldelli; Bellezza, Guido; A., Flacco; Ragusa, Mark; Valigi, Paolo; Crino', Lucio | |
| Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc) | 2012 | Cappuzzo, F; Sacconi, A; Landi, L; Biagioni, F; Ludovini, V; Sensi, E; Salvini, J; Fontanini, G; Blandino, G; Crino', Lucio | |
| Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial | 2012 | Ardizzoni, A; Tiseo, M; Boni, L; Vincent, Ad; Passalacqua, R; Buti, S; Amoroso, D; Camerini, A; Labianca, R; Genestreti, G; Boni, C; Ciuffreda, L; Costanzo, Fd; De Marinis, F; Crino', Lucio; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Mattioli, R; Cafferata, Ma; Camisa, R; Smit, Ef | |
| Updated Results of A Global Phase II Study With Crizotinib In Advanced Alk-positive Non-small Cell Lung Cancer (NSCLC) | 2012 | Kim, D; Ahn, M; Yan, g P; Li, u X; Pas, Td; Crino', Lucio; Lanzalone, S; Polli, A; Shaw, A. | |
| A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. | 2012 | Riely, Gj; Brahmer, Jr; Planchard, D; Crino', Lucio; Doebele, Rc; Lopez, Lam; Gettinger, Sn; Schumann, C; Li, Xy; Atkins, Bm; Ebbinghaus, S; Rosell, R. | |
| First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer | 2012 | Bearz, A; Passalacqua, R; Alabiso, O; Cinieri, S; Gridelli, C; Cravesana, C; Crino', Lucio | |
| Emerging drugs for small cell lung cancer - an update | 2012 | Metro, G; Duranti, S; Fischer, Mj; Cappuzzo, F; Crino', Lucio | |
| Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. | 2012 | Normanno, N; Pinto, C; Taddei, Gl; Troncone, G; Graziano, P; Maglio, Gd; Mottolese, M; Ludovini, V; Zupo, S; Larocca, Lm; Roz, E; Russo, A; Palmieri, G; Perrone, G; Maio, Md; Ardizzoni, A; Crino', Lucio; Perrone, G; Clemente, C; Marchetti, A. | |
| Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer A Phase-II Study | 2012 | Scagliotti, Gv; Ilaria, R; Novello, S; Von Pawel, J; Fischer, Jr; Ermisch, S; De Alwis, Dp; Andrews, J; Reck, M; Crino', Lucio; Eschbach, C; Manegold, C. | |
| Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). | 2012 | Janne, Pa; Shaw, At; Pereira, Jr; Jeannin, G; Vansteenkiste, J; Barrios, Ch; Franke, Fa; Grinsted, L; Smith, Pd; Zazulina, V; Smith, Ic; Crino', Lucio | |
| Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study | 2012 | Faggiano, A; Grimaldi, F; Manzoni, M; Davi, Mv; Ferone, D; Giuffrida, D; Roiter, I; Fanciulli, G; Papini, E; Martini, C; Franchi, Gm; Fasola, G; Albertelli, M; Crino', Lucio; Colao, A; Ferolla, Piero | |
| Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype | 2012 | Metro, G; Chiari, R; Duranti, S; Siggillino, Annamaria; Fischer, Mj; Giannarelli, D; Ludovini, V; Bennati, C; Marcomigni, L; Baldi, A; Giansanti, M; Minotti, V; Crino', Lucio | |
| An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy | 2012 | Grunwald, V; Karakiewicz, Pi; Bavbek, Se; Miller, K; Machiels, Jp; Lee, Sh; Larkin, J; Bono, P; Rha, Sy; Castellano, D; Blank, Cu; Knox, Jj; Hawkins, R; Anak, O; Rosamilia, M; Booth, J; Pirotta, N; Bodrogi, I; Crino', Lucio; REACT Study, Group | |
| Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? | 2012 | Metro, G; Minotti, V; Crino', Lucio | |
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | 2012 | Miller, Va; Hirsh, V; Cadranel, J; Chen, Ym; Park, K; Kim, Sw; Zhou, Cc; Su, Wc; Wang, Mz; Sun, Y; Heo, Ds; Crino', Lucio; Tan, Eh; Chao, Ty; Shahidi, M; Cong, Xj; Lorence, Rm; Yang, Hjc |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile